Results 141 to 150 of about 30,982 (215)

Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case–Control Study

It is important to understand real-world BNT162b2 COVID-19 vaccine effectiveness (VE), especially among racial and ethnic minority groups. We performed a test-negative case-control study to measure BNT162b2 COVID-19 VE in the prevention of COVID-19 ...
Larry J. Anderson, Srinivas Rao Valluri, Caroline Ciric, Ben A. Lopman, Meg Taylor, Luis Salazar, Laura Puzniak, Chris Choi, Timothy L. Wiemken, Satoshi Kamidani, Evan J. Anderson, Amy Keane, Khalel De Castro, Anna Mitchell, John M. McLaughlin, Elizabeth Grace Taylor, Robin Hubler, Christina A. Rostad, Ashley Tippett, Olivia Reese, Theda Gibson   +20 more
core   +1 more source

Boosting capacity of a fourth dose BNT162b2 in cancer patients

European Journal of Cancer, 2023
Debie, Yana, van Dam, Peter A, Goossens, Maria E, Peeters, Marc, Vandamme, Timon   +4 more
openaire   +3 more sources

Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents. [PDF]

Hum Vaccin Immunother
Olagunju OJ, Oyebanji OA, Keresztesy D, Wilk D, Dickerson E, Wallace T, Holland L, Payne M, See E, Li CJ, Lim E, Abul Y, Nugent C, Balazs AB, Bosch J, King CL, Wilson B, Gravenstein S, Canaday DH.   +18 more
europepmc   +1 more source

Role of plasmacytoid dendritic cells in humoural and CD8⁺ T-cell memory responses following BNT162b2 mRNA vaccination: a preclinical mouse study. [PDF]

EBioMedicine
Pizzichetti C, Latino I, Virgilio T, Capucetti A, Chahine K, Cascione L, Moro SG, Bilato G, Brügger M, Kozarac N, Pulfer A, Renner L, Thakur RS, Benarafa C, Legler DF, González SF.   +15 more
europepmc   +1 more source

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults. [PDF]

Vaccines (Basel)
Puebla YP, Nicholls H, Fitz-Patrick D, Horton LE, Gawel MW, Martinez RD, Wang X, Keep G, Xu X, Gomme E, Scully I, Allen PS, Swanson KA, Salisch N, Mensa FJ, Rizzi R, Türeci Ö, Şahin U, Anderson AS, Gurtman A, Lindert KA.   +20 more
europepmc   +1 more source

Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

New England Journal of Medicine, 2021
Mark G, Thompson, Lauren, Grant, Jennifer, Meece   +2 more
openaire   +5 more sources

Differential functional immune recall across homologous and heterologous COVID-19 vaccination regimens. [PDF]

Front Immunol
Che-Kamaruddin N, Johari J, Yahaya H, Zainal N, Nguyen HC, Hontz RD, Letizia AG, AbuBakar S.   +7 more
europepmc   +1 more source

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults. [PDF]

Vaccines (Basel)
Praphasiri P, Ditsungneon D, Kerdsin A, Nakphook S, Kittiwatanachod J, Sornwong K, Naosri S, Khunarsa S, Wirachwong P, Techatanawat I, Narakorn P, Surichan S, Flores J, Mercer LD, Polyak CS, Innis BL, Raghunandan R, Pittayawonganon C, Iamsirithaworn S, Sirilak S, Prasert K.   +20 more
europepmc   +1 more source

Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy-Treated People With HIV. [PDF]

Open Forum Infect Dis
Mitha E, Berhe M, Aberg J, Lucasti CJ, Chalhoub F, Kitchin N, Vogler I, Lockhart SP, Fuchs S, Quandt J, Gruber WC, Webber C, Kühnle MC, Muik A, Lui BG, Vehreschild MJGT, Stephan C, Bushway M, Xu X, Belanger TJ, Trammel Price J, Liebscher S, Bailey R, Mather S, Adams EM, Shpyro S, Lagkadinou E, Türeci Ö, Swanson KA, Şahin U, Gurtman A.   +30 more
europepmc   +1 more source

Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study. [PDF]

Vaccines (Basel)
Waghmare A, Dadhe R, Kobbe R, Danziger-Isakov L, Sprinz E, Muñoz FM, Gayed J, Solan R, Diya O, Abraham B, Feng Y, Xu X, Belanger T, Mensa FJ, Girardin R, Türeci Ö, Şahin U, Modjarrad K, Swanson KA, Anderson AS, Gurtman A, Kitchin N.   +21 more
europepmc   +1 more source